Overview

• The 2 mg single-dose spray is approved for adults and children weighing at least 30 kg and delivers its full contents even if users have blocked noses.
• It marks the UK’s first non-injectable anaphylaxis treatment after a separate review from the US approval in August 2024.
• MHRA guidance urges patients to carry two sprays and inform family or friends of their location in case a second dose is needed.
• A company spokeswoman said a UK market launch could occur in coming months pending price agreement with the Department of Health.
• Detailed usage instructions and preparedness resources are now available on the MHRA website to support rapid and correct administration.